Esophageal Cancer
Conditions
Keywords
Esophageal cancer, Chemoradiotherapy, Paclitaxel, Cetuximab
Brief summary
We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (TP-CCRT) as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal squamous cell carcinoma (ESCC).
Detailed description
We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal squamous cell carcinoma.
Interventions
DRUGCetuximab
Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
DRUGPaclitaxel
T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
DRUGCisplatin
P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
RADIATIONRadiotherapy
Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
Sponsors
National Taiwan University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically proven squamous cell carcinoma of esophagus. 2. Loco-regional diseases, which are defined by TNM system of American Joint Committee on Cancer (AJCC) Cancer Staging System (6th edition) in 2002, fulfilling one of the following criteria: A. T3, N0, M0; B. T1-3, N1, M0; C. T1-3 or N0-1, M1a will be eligible provided the lesions could be covered by appropriate radiation fields. 3. Age ≥ 18 years old. 4. Performance status ECOG 0\ 2. 5. Adequate bone marrow reserves, defined as: A. white blood cells (WBC) ≥ 4,000/µl or neutrophil count (ANC) ≥ 2,000/µl; B. platelets ≥ 100,000/µl. 6. Adequate liver function reserves, defined as: A. hepatic transaminases ≤ 2.5 x upper limit of normal (ULN); B. serum total bilirubin ≤ 1.5 x upper limit of normal (ULN). 7. Adequate renal function: Creatinine ≤1.5 mg/dl 8. Written informed consent.
Exclusion criteria
1. Invasion to surrounding organ (T4 disease). 2. Distant metastasis, except M1a disease listed in the inclusion criteria 2-C. 3. Adenocarcinoma of gastroesophageal (GE) junction. 4. Prior thoracic irradiation. 5. Synchronously diagnosed squamous cell carcinoma of aerodigestive way, other than esophageal cancer. 6. Prior malignancy, except for the following: A. adequately treated basal cell or squamous cell skin cancer; B. in-situ cervical cancer; C. Note: previously treated aerodigestive squamous cell carcinoma is not allowed. 7. Significant co-morbid disease, which prohibit the conduction of chemotherapy, concurrent chemoradiotherapy, or radical surgery, such as active systemic infection, symptomatic cardiac or pulmonary disease, or psychiatric disorders. 8. Estimated life expectancy less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy). | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Pathologic complete response (pCR). | 2 years |
| Disease-free survival. | 2 years |
| Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery. | 2 years |
Countries
Taiwan
Contacts
Primary ContactChih-Hung Hsu, M.D., Ph.D.
Outcome results
None listed